Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4 count at death among HIV-infected persons in care in the US, Althoff KN, et al, for the North American AIDS Cohort Collaboration on Research and Design

Trends in ART use, HIV viral load, and CD4 count at death among HIV-infected persons in care in the US, Althoff KN, et al, for the North American AIDS Cohort Collaboration on Research and Design Figure 3: Trends in the proportion with suppressed (≤2.7 log 10 or ≤500 copies/mL) HIV VL and mid- year HIV VL, by antiretroviral therapy status % suppressed increased from 46% to 72%, regardless of treatment

Trends in ART use, HIV viral load, and CD4 count at death among HIV-infected persons in care in the US, Althoff KN, et al, for the North American AIDS Cohort Collaboration on Research and Design Figure 4: Median CD4 count within 18 months prior to death (N=4,417 decedents) Median CD4 count tripled to 209 cells/mm 3

Trends in ART use, HIV viral load, and CD4 count at death among HIV-infected persons in care in the US, Althoff KN, et al, for the North American AIDS Cohort Collaboration on Research and Design Figure 1: Unadjusted percentages of PLWH-US within 50 states and the District of Columbia, that were alive and in care among US clinical cohorts participating in the NA-ACCORD, (N=23,884), by state, year-end 2008 % of NA-ACCORD participants among the unadjusted estimate of PLWH-US in all 50 states and DC at the end of 2008 was 3.1% (26,030/831,578)